Renaissance Capital logo

NVCR News

Cancer zapping device company Pulse Biosciences prices IPO at $4, as expected

PLSE

Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, raised $20 million by offering 5 million shares at $4, as expected. At $4 per share, Pulse commands a diluted market cap of $51 million. NovoCure (NVCR), which markets a wearable electric field device for brain cancer, raised $165 million at a $2.1 billion...read more

US IPO Weekly Recap: Only five deals get done after massive valuation cuts

CERCU

Home, home below the range: all five deals this week priced below the range.  There were eleven companies on the IPO calendar this week, but only five were able to price, and each of those priced at least 19% below their...read more

NovoCure prices IPO at $22, below the downwardly revised range

NVCR

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, raised $165 million by offering 7.5 million shares (all primary) at $22, below the downwardly revised range of $23 to $24. The company originally planned to offer 12.5 million shares, including 5 million secondary shares, at $26 to $29. NovoCure plans to list on the Nasdaq under the...read more

NovoCure slashes range and removes insider selling ahead of $176 million IPO

NVCR

NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday. The St Helier, Jersey-based company now plans to raise $176 million by offering 7.5 million shares at a price range of $23 to $24. The company had previously filed to offer 12.5 million shares (5...read more